
Insilico Medicine Nominates Pan-KRAS Preclinical Candidate ISM6166 to Tackle “Undruggable” Solid Tumors, Showing Tumor Regression in Preclinical Studies
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxPVkFvZzI3R3dBb0NsR0xodkdOZ1dQOTN5MmxoT2NrM2pkZDBwZ3ZzenZObExXZVVCM1UyQ1dQRjZRNnpMSmdYcVctQUFRVHhFQVVYd2hWZ3otSXdtZkRFNFNabnJxZ1RYN24wQ05uY2VDRDNBdUNoMFNIbV9hVVlHZmpjbw?oc=5" target="_blank">Insilico Medicine Nominates Pan-KRAS Preclinical Candidate ISM6166 to Tackle “Undruggable” Solid Tumors, Showing Tumor Regression in Preclinical Studies</a>&nbsp;&nbsp;<font color="#6f6f6f">Insilico Medicine</font>
